# Keros Therapeutics, Inc.: financial statements, quarterly

KROS · Nasdaq · CIK 1664710 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/kros.md) · [Financials](/companies/kros/financials.md) · [Filings](/companies/kros/filings.md) · [Insiders](/companies/kros/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/kros/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001664710-24-000091.md) | [0.1 d](/filings/0001664710-25-000018.md) | [0.1](/filings/0001664710-25-000046.md) | [0.0](/filings/0001664710-25-000070.md) | [0.4](/filings/0001664710-25-000089.md) | [3.0 d](/filings/0001664710-26-000018.md) | [211](/filings/0001664710-26-000030.md) | [18.2](/filings/0001664710-26-000049.md) | [14.3](/filings/0001664710-25-000089.md) | [0.4 d](/filings/0001664710-26-000018.md) | [0.4](/filings/0001664710-26-000030.md) | [0.0](/filings/0001664710-26-000049.md) |
| Research and development | $m | [34.1](/filings/0001664710-24-000091.md) | [37.5 d](/filings/0001664710-25-000018.md) | [38.3](/filings/0001664710-25-000046.md) | [40.5](/filings/0001664710-25-000070.md) | [49.2](/filings/0001664710-25-000089.md) | [45.6 d](/filings/0001664710-26-000018.md) | [48.7](/filings/0001664710-26-000030.md) | [43.5](/filings/0001664710-26-000049.md) | [19.5](/filings/0001664710-25-000089.md) | [17.9 d](/filings/0001664710-26-000018.md) | [16.1](/filings/0001664710-26-000030.md) | [22.3](/filings/0001664710-26-000049.md) |
| Operating income | $m | [(43.3)](/filings/0001664710-24-000091.md) | [(46.5) d](/filings/0001664710-25-000018.md) | [(48.5)](/filings/0001664710-25-000046.md) | [(50.4)](/filings/0001664710-25-000070.md) | [(58.7)](/filings/0001664710-25-000089.md) | [(53.3) d](/filings/0001664710-26-000018.md) | [152](/filings/0001664710-26-000030.md) | [(39.8)](/filings/0001664710-26-000049.md) | [(15.4)](/filings/0001664710-25-000089.md) | [(29.3) d](/filings/0001664710-26-000018.md) | [(25.9)](/filings/0001664710-26-000030.md) | [(30.9)](/filings/0001664710-26-000049.md) |
| Income tax | $m | not reported | not reported | [0.0](/filings/0001664710-25-000046.md) | [0.0](/filings/0001664710-25-000070.md) | [0.0](/filings/0001664710-25-000089.md) | [0.3 d](/filings/0001664710-26-000018.md) | [10.0](/filings/0001664710-26-000030.md) | [(2.2)](/filings/0001664710-26-000049.md) | [(1.4)](/filings/0001664710-25-000089.md) | [(1.5) d](/filings/0001664710-26-000018.md) | [0.0](/filings/0001664710-26-000030.md) | [0.0](/filings/0001664710-26-000049.md) |
| Net income | $m | [(39.4)](/filings/0001664710-24-000091.md) | [(40.2) d](/filings/0001664710-25-000018.md) | [(43.1)](/filings/0001664710-25-000089.md) | [(45.3)](/filings/0001664710-25-000089.md) | [(53.0)](/filings/0001664710-25-000089.md) | [(46.0) d](/filings/0001664710-26-000018.md) | [148](/filings/0001664710-26-000049.md) | [(30.7)](/filings/0001664710-26-000049.md) | [(7.3)](/filings/0001664710-25-000089.md) | [(23.5) d](/filings/0001664710-26-000018.md) | [(23.7)](/filings/0001664710-26-000049.md) | [(28.7)](/filings/0001664710-26-000049.md) |
| Diluted EPS | $ per share | [(1.33)](/filings/0001664710-24-000091.md) | not reported | [(1.21)](/filings/0001664710-25-000046.md) | [(1.25)](/filings/0001664710-25-000070.md) | [(1.41)](/filings/0001664710-25-000089.md) | not reported | [3.62](/filings/0001664710-26-000030.md) | [(0.76)](/filings/0001664710-26-000049.md) | [(0.18)](/filings/0001664710-25-000089.md) | not reported | [(1.21)](/filings/0001664710-26-000030.md) | [(1.45)](/filings/0001664710-26-000049.md) |
| Basic EPS | $ per share | [(1.33)](/filings/0001664710-24-000091.md) | not reported | [(1.21)](/filings/0001664710-25-000046.md) | [(1.25)](/filings/0001664710-25-000070.md) | [(1.41)](/filings/0001664710-25-000089.md) | not reported | [3.66](/filings/0001664710-26-000030.md) | [(0.76)](/filings/0001664710-26-000049.md) | [(0.18)](/filings/0001664710-25-000089.md) | not reported | [(1.21)](/filings/0001664710-26-000030.md) | [(1.45)](/filings/0001664710-26-000049.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [288](/filings/0001664710-24-000091.md) | [331](/filings/0001664710-25-000018.md) | [442](/filings/0001664710-25-000046.md) | [406](/filings/0001664710-25-000070.md) | [531](/filings/0001664710-25-000089.md) | [560](/filings/0001664710-26-000018.md) | [721](/filings/0001664710-26-000030.md) | [690](/filings/0001664710-26-000049.md) | [693](/filings/0001664710-25-000089.md) | [287](/filings/0001664710-26-000049.md) | [281](/filings/0001664710-26-000030.md) | [258](/filings/0001664710-26-000049.md) |
| Current assets | $m | [304](/filings/0001664710-23-000066.md) | [347](/filings/0001664710-25-000018.md) | [463](/filings/0001664710-24-000039.md) | [433](/filings/0001664710-24-000068.md) | [552](/filings/0001664710-24-000091.md) | [589](/filings/0001664710-26-000018.md) | [760](/filings/0001664710-25-000046.md) | [733](/filings/0001664710-25-000070.md) | [719](/filings/0001664710-25-000089.md) | [315](/filings/0001664710-26-000049.md) | [291](/filings/0001664710-26-000030.md) | [267](/filings/0001664710-26-000049.md) |
| Total assets | $m | [326](/filings/0001664710-23-000066.md) | [370](/filings/0001664710-25-000018.md) | [486](/filings/0001664710-24-000039.md) | [455](/filings/0001664710-24-000068.md) | [579](/filings/0001664710-24-000091.md) | [616](/filings/0001664710-26-000018.md) | [785](/filings/0001664710-25-000046.md) | [757](/filings/0001664710-25-000070.md) | [743](/filings/0001664710-25-000089.md) | [338](/filings/0001664710-26-000049.md) | [312](/filings/0001664710-26-000030.md) | [288](/filings/0001664710-26-000049.md) |
| Current liabilities | $m | [16.7](/filings/0001664710-23-000066.md) | [24.4](/filings/0001664710-25-000018.md) | [18.7](/filings/0001664710-24-000039.md) | [21.2](/filings/0001664710-24-000068.md) | [29.0](/filings/0001664710-24-000091.md) | [27.5](/filings/0001664710-26-000018.md) | [39.4](/filings/0001664710-25-000046.md) | [34.7](/filings/0001664710-25-000070.md) | [24.1](/filings/0001664710-25-000089.md) | [20.4](/filings/0001664710-26-000049.md) | [12.9](/filings/0001664710-26-000030.md) | [12.2](/filings/0001664710-26-000049.md) |
| Total liabilities | $m | [30.4](/filings/0001664710-23-000066.md) | [37.8](/filings/0001664710-25-000018.md) | [31.9](/filings/0001664710-24-000039.md) | [34.1](/filings/0001664710-24-000068.md) | [46.4](/filings/0001664710-24-000091.md) | [44.3](/filings/0001664710-26-000018.md) | [55.7](/filings/0001664710-25-000046.md) | [50.4](/filings/0001664710-25-000070.md) | [39.2](/filings/0001664710-25-000089.md) | [34.9](/filings/0001664710-26-000049.md) | [26.7](/filings/0001664710-26-000030.md) | [25.3](/filings/0001664710-26-000049.md) |
| Shareholders' equity | $m | [296](/filings/0001664710-24-000091.md) | [332](/filings/0001664710-26-000018.md) | [454](/filings/0001664710-25-000089.md) | [421](/filings/0001664710-25-000089.md) | [533](/filings/0001664710-25-000089.md) | [572](/filings/0001664710-26-000049.md) | [729](/filings/0001664710-26-000049.md) | [707](/filings/0001664710-26-000049.md) | [704](/filings/0001664710-25-000089.md) | [303](/filings/0001664710-26-000049.md) | [286](/filings/0001664710-26-000049.md) | [262](/filings/0001664710-26-000049.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(34.0) d](/filings/0001664710-24-000091.md) | [(25.5) d](/filings/0001664710-25-000018.md) | [(44.6)](/filings/0001664710-25-000046.md) | [(39.8) d](/filings/0001664710-25-000070.md) | [(30.5) d](/filings/0001664710-25-000089.md) | [(46.0) d](/filings/0001664710-26-000018.md) | [161](/filings/0001664710-26-000030.md) | [(29.6) d](/filings/0001664710-26-000049.md) | [3.2 d](/filings/0001664710-25-000089.md) | [(27.3) d](/filings/0001664710-26-000018.md) | [(3.5)](/filings/0001664710-26-000030.md) | [(20.4) d](/filings/0001664710-26-000049.md) |
| Capital expenditure | $m | [0.6 d](/filings/0001664710-24-000091.md) | [0.5 d](/filings/0001664710-25-000018.md) | [0.9](/filings/0001664710-25-000046.md) | [0.3 d](/filings/0001664710-25-000070.md) | [0.4 d](/filings/0001664710-25-000089.md) | [0.3 d](/filings/0001664710-26-000018.md) | [0.6](/filings/0001664710-26-000030.md) | [0.7 d](/filings/0001664710-26-000049.md) | [0.1 d](/filings/0001664710-25-000089.md) | [0.1 d](/filings/0001664710-26-000018.md) | [0.1](/filings/0001664710-26-000030.md) | [0.2 d](/filings/0001664710-26-000049.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [25.5](/filings/0001664710-23-000066.md) | [28.4](/filings/0001664710-24-000039.md) | [29.6](/filings/0001664710-24-000068.md) | [29.7](/filings/0001664710-24-000091.md) | [35.7](/filings/0001664710-25-000046.md) | [36.1](/filings/0001664710-25-000070.md) | [37.6](/filings/0001664710-25-000089.md) | [41.0](/filings/0001664710-26-000030.md) | [40.6](/filings/0001664710-26-000049.md) | [40.6](/filings/0001664710-25-000089.md) | [19.6](/filings/0001664710-26-000030.md) | [19.8](/filings/0001664710-26-000049.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 19,827,188 at 2026-07-27, from the cover of the [10-Q filed 2026-08-03](/filings/0001664710-26-000049.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.